IBI318
Phase 1Small molecule
Innovent Biologics (Suzhou) Co. Ltd.IBI318 is one of 125 small molecule programs targeting Cutaneous Squamous Cell Carcinoma. It is currently in Phase 1.
4
Indications
6
Total Trials
1
Active Trials
124
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Velban
EEastern Cooperative Oncology Group
Preclinical
Zofran
NovartisPreclinical
Wellcovorin
GGlaxo Dba Glaxosmithkline
Preclinical
Tafasitamab
IncytePreclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Nuvigil
NNuvo Research GmbH
Preclinical
IBI318
Innovent Biologics (Suzhou) Co. Ltd.Phase 1
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hepatocellular Carcinoma1 trial
Cutaneous Squamous Cell Carcinoma1 trial
Small Cell Lung Cancer1 trial
Efficacy and Safety1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IBI318. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details